All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EDP-721
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: EDP-721
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2021
Details:
Enanta Pharmaceuticals announces New Oral Hbv Rna Destabilizer, EDP-721, as an additional component toward functional HBV Cure; expects to initiate phase 1 study mid-2021.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: $470.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration December 10, 2020
Details:
HemoShear Therapeutics has achieved a research milestone in its discovery and development collaboration with Takeda Pharmaceutical Company Limited to advance its first nonalcoholic steatohepatitis (NASH) target into Takeda’s discovery portfolio.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SRT-015
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: SRT-015
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2020
Details:
The presentations demonstrate superior pharmacological properties of SRT-015 compared to other ASK1 inhibitors, including selonsertib, and provide potential explanations for the failure of selonsertib in clinical trials.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TXR-611
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TXR-611
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2020
Details:
In vivo efficacy with TXR-611 and 612 was evaluated using STAM™ mouse model where hits showed good tolerability and significant decrease in liver weight, steatosis, ballooning, fibrillar collagen deposition, NAFLD activity score and efficacy compares favorably to telmisartan.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Hydroxyl dendrimer
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2020
Details:
Ashvattha has developed a novel hepatocyte targeted hydroxyl dendrimer therapeutic which enables selective targeting of farnesoid X receptor agonists on hepatocytes through the asialoglycoprotein receptor mediated uptake after systemic administration.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SRT-015
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: SRT-015
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2020
Details:
Posters to highlight excellent efficacy of SRT-015 in NASH-relevant models, and comparator data with the ASK1 inhibitor selonsertib that is consistent with its lack of efficacy in phase 3 trials.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SZN-043
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: SZN-043
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $2.0 million Upfront Cash: $1.0 million
Deal Type: Funding October 15, 2020
Details:
SZN-043, is currently in preclinical development for severe alcoholic hepatitis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BOS-580
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: BOS-580
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Boston Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 01, 2020
Details:
Under the terms of the agreement, Boston Pharmaceuticals will license worldwide development and commercial rights to the drug candidate BOS-580, for the treatment of Non-Alcoholic Steatohepatitis (NASH) from Novartis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ALT-801
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: ALT-801
Highest Development Status: Preclinical Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 01, 2020
Details:
The Company believes the data provide clear validation of previously observed pharmacodynamic effects of ALT-801 and pave the way for the anticipated Phase 1 single and multiple ascending dose clinical trials following submission of a clinical trail application in Australia.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ALT-801
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: ALT-801
Highest Development Status: Preclinical Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 26, 2020
Details:
ALT-801 demonstrated statistically superior reductions (p ≤ 0.05) in body weight, liver weight, plasma ALT, liver triglycerides and cholesterol, plasma cholesterol, NAFLD activity scores, and fibrosis markers compared to semaglutide.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
